Search

everythinglearnresearchcommunity

for

Search:↓

Men who start losing hair at 20 may have a higher chance of getting prostate cancer later.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

PCOS is linked to a higher risk of endometrial cancer but not ovarian or breast cancer, and more research is needed on its role in cancer development and treatment effects.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

Certain natural compounds called terpenes may help prevent prostate cancer.

Physical activity, height, and smoking affect prostate cancer risk.

PCOS may increase the risk of certain cancers.

The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.

Androgen deprivation therapy doesn't lower the risk of death from COVID-19 in prostate cancer patients.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

Antioxidants can block the cancer-fighting effects of doxorubicin.

Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.

Higher BMI and lower testosterone are linked to more aggressive prostate cancer.

Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.

Plant-based compounds might be a promising alternative for prostate cancer treatment with fewer side effects.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

Analog 23 is a promising compound for prostate cancer treatment.

The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

Liquorice may reduce testosterone and affect male reproductive organs, potentially helping treat conditions like prostate cancer.

Spironolactone does not increase cancer risk and may lower prostate cancer risk, but more research is needed.

Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.

Most men with lichen planopilaris had it confirmed by biopsy and often had thyroid issues, sexual dysfunction, or prostate cancer, hinting at a link with hormonal problems.

Breast cancer survivors may have a higher risk of falls, tamoxifen could prevent breast cancer and deaths, new guidelines urge caution with prostate cancer therapy, and early balding in men may indicate a higher prostate cancer risk.

New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.

New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.